Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sensorion SAS (DE:RFM)
FRANKFURT:RFM
Holding DE:RFM?
Track your performance easily
RFM Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.38 - €0.98
Previous Close€0.63
Volume0.00
Average Volume (3M)N/A
Market Cap
€206.70M
Enterprise Value€184.35M
Total Cash (Recent Filing)€26.20M
Total Debt (Recent Filing)€3.85M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Mar 13, 2025EPS Estimate
-€0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)6.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.25Price Target Upside257.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentALSEN has the potential to take the lead in clinical development for GJB2-mediated hearing loss, as competitors have not yet made it to the clinic.
Market OpportunityThe potential market opportunity for GJB2 is larger than that expected for the company's currently gene therapy asset.
Preclinical DataEncouraging preclinical data was presented showing high and persistent GJB2 expression in the intended target cells with limited off-target detection and no hair-cell loss or ototoxicity.
Bears Say
Clinical EfficacyThis delay for initial proof of clinical efficacy is a disappointment relative to investors’ expectations.
Competitive ComparisonLack of numerical data makes comparison to competitors challenging at this point.
Study ResultsResults of the first 16 patients (out of a total of approximately 60) show no difference in hearing loss between the treated and the control arms.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
6.81% Mutual Funds
― Other Institutional Investors
93.19% Public Companies and
Individual Investors
RFM FAQ
What was Sensorion SAS’s price range in the past 12 months?
Sensorion SAS lowest stock price was €0.38 and its highest was €0.98 in the past 12 months.
What is Sensorion SAS’s market cap?
Currently, no data Available
When is Sensorion SAS’s upcoming earnings report date?
Sensorion SAS’s upcoming earnings report date is Mar 13, 2025 which is in 111 days.
How were Sensorion SAS’s earnings last quarter?
Sensorion SAS released its earnings results on Sep 18, 2024. The company reported -€0.05 earnings per share for the quarter, beating the consensus estimate of -€0.07 by €0.02.
Is Sensorion SAS overvalued?
According to Wall Street analysts Sensorion SAS’s price is currently Undervalued.
Does Sensorion SAS pay dividends?
Sensorion SAS does not currently pay dividends.
What is Sensorion SAS’s EPS estimate?
Sensorion SAS’s EPS estimate is -€0.06.
How many shares outstanding does Sensorion SAS have?
Sensorion SAS has 300,501,220 shares outstanding.
What happened to Sensorion SAS’s price movement after its last earnings report?
Sensorion SAS reported an EPS of -€0.05 in its last earnings report, beating expectations of -€0.07. Following the earnings report the stock price went down -1.136%.
Which hedge fund is a major shareholder of Sensorion SAS?
Currently, no hedge funds are holding shares in DE:RFM
---
Sensorion SAS Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.09%
12-Months-Change
Fundamentals
Return on Equity
-50.75%
Trailing 12-Months
Asset Growth
268.74%
Trailing 12-Months
Company Description
Sensorion SAS
Sensorion SA is a France-based clinical-stage biotech company dedicated to the development of innovative therapies to restore, treat and prevent hearing loss. The company's product is in Phase 2 clinical development, SENS-401 (Arazasetron) in Sudden Sensorineural Hearing Loss (SSNHL). SENS-401 is being developed to treat cochlear pathologies.
---
RFM Stock 12 Month Forecast
Average Price Target
€2.25
▲(257.14% Upside)
Technical Analysis
Best Analysts Covering RFM
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+10.91%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +10.91% per trade.
---